The Dose Makes The Poison
April 8, 2015 10:15 AM Subscribe
Ellie Lobel was 27 when she was bitten by a tick and contracted Lyme disease. And she was not yet 45 when she decided to give up fighting for survival. ... “Nothing was working any more, and nobody had any answers for me,” she says. “Doctors couldn’t help me. I was spending all this cash and was going broke, and when I got my last test results back and all my counts were just horrible, I knew right then and there that this was the end.” ... So she packed up everything and moved to California to die. And she almost did. Less than a week after moving, Ellie was attacked by a swarm of Africanised bees.
The Antimicrobial Agent Melittin Exhibits Powerful In Vitro Inhibitory Effects on the Lyme Disease Spirochete [PDF], Lori L. Lubke and Claude F. Garon, From the Bacterial Pathogenesis Section, Rocky Mountain Laboratories Microscopy Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana
The American Cancer Society on apitherapy
The Structure of Melittin[PDF], Terwilliger and Eisenber, The Journal of Biological Chemistry, vol 257, no 11.
Melittin: a membrane-active peptide with diverse functions, Raghuraman H, Chattopadhyay A. Biosci Rep. 2007 Oct;27(4-5):189-223.
Melittin: A lytic peptide with anticancer properties, Goran Gajski, Vera Garaj-Vrhovac. Environmental Toxicology and Pharmacology: Volume 36, Issue 2, September 2013, Pages 697–705.
Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth. J Clin Invest. 2009;119(9):2830–2842. doi:10.1172/JCI38842. Neelesh R. Soman, Steven L. Baldwin, Grace Hu, Jon N. Marsh, Gregory M. Lanza, John E. Heuser, Jeffrey M. Arbeit, Samuel A. Wickline and Paul H. Schlesinger
Process of inducing pores in membranes by melittin, Ming-Tao Lee, 14243–14248, doi: 10.1073/pnas.1307010110
Cytolytic nanoparticles attenuate HIV-1 infectivity, Joshua L Hood, Andrew P Jallouk, Nancy Campbell, Lee Ratner, Samuel A Wickline. Antiviral Therapy 2013; 18:95-103
Influence of amphipathic peptides on the HIV-1 production in persistently infected T lymphoma cells, Michael Wachinger, Torben Saermark, Volker Erfle
Theraputic Potential of Venom Peptides[PDF] (PubMed, Nat Rev Drug Discov. 2003 Oct;2(10):790-802, Richard J. Lewis and Maria L. Garcia:
Venomous animals have evolved a vast array of peptide toxins for prey capture and defence.
These peptides are directed against a wide variety of pharmacological targets, making them an
invaluable source of ligands for studying the properties of these targets in different experimental
paradigms. A number of these peptides have been used in vivo for proof-of-concept studies,
with several having undergone preclinical or clinical development for the treatment of pain,
diabetes, multiple sclerosis and cardiovascular diseases. Here we survey the pharmacology of
venom peptides and assess their therapeutic prospects.
Bee Venom and HIV are we getting stung again?
Interesting? Very. Provocative? Certainly. Proof of Bee Venom generalized effectiveness? Unequivocal no. This is preliminary research only. There is a chance that a component of bee venom may be an agent that can be used to interfere with the transmission of HIV. I stress MAY here.From Toxins to Therapeutics
previously:Cancer cells, COVERED IN BEES!, A scorpion-venom concoction that makes tumors glow sounds almost too outlandish to be true.
This thread has been archived and is closed to new comments